Dean G Tang

Oncology — Roswell Park Cancer Institute, United States

LeadR Profile

Dean G Tang Roswell Park Cancer Institute United States
1 272 ScienceLeadR Reputation 1272
Network Map

Oncology

Subspecialties: Biochemistry - Hematology - Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026

Source: PubMed

Roswell Park Cancer Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 215

Citations

Citations: 17 821 1st author: 33 Last author: 100 Unique author: 5


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.
cells, neoplasms, prostate, sarcoma, prostatic neoplasms, therapeutics
J Exp Clin Cancer Res20260
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.
cells, genes, bcl-2, neoplasms, prostate, prostatic neoplasms, signal transduction, castration, therapeutics, heterografts
Signal Transduct Target Ther Top journal20260
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma.
growth, androgens, rhombencephalon, brain, sex, ependymoma, child
Nature Top journal20261
The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.
cells, androgens, macrophages, cold temperature, neoplasms, prostate, prostatic neoplasms, immunity, therapeutics, tumor-associated macrophages, t-lymphocytes, helper-inducer
medRxiv20260
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
neoplasms, prostate, prostatic neoplasms, castration, therapeutics
Cancer Chemother Pharmacol20250

LeadR Networks

Main global connection map